Drugs / AZD5213
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT01335451 | Apr → Oct 2011 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01194986 | Nov 2010 → Jun 2011 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01171105 | Jul 2010 → May 2011 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01121302 | May → Dec 2010 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT01928381 | Nov 2013 → May 2015 | diabetic neuropathy | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT01904773 | Aug 2013 → Feb 2015 | Tourette syndrome | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT01548287 | Apr 2012 → Jan 2013 | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD5213 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01904773 ↗ |
| Route | Oral | “single oral doses” NCT01121302 ↗ |